ARCH Venture Entities and Paul Berns Buy $18M of ASPE at $15.00 IPO Price
ASPE is trading near its 52-week low of $11.6 (13% above the low).
Summary
ARCH Venture funds and Paul Berns bought 1.2 million ASPE shares at $15.00 for $18 million on the day the IPO closed, matching the IPO price.
Key Events · Ownership and Investor Activity · ASPE
-
ARCH Group Buys $18M at IPO Price
ARCH Venture Fund XIV and affiliated entities plus Paul Berns acquired 1,200,000 shares at $15.00 for $18,000,000 in a single open-market purchase on 2026-11-02.
-
Purchase Priced at IPO Level
The $15.00 purchase price equals the IPO price, which sat at the bottom of the $15-$17 range; the stock trades at $13.13 as of 2026-11-02, below that level.
-
Sponsor Group Holds 1.2M Shares
Post-transaction holdings are 1,200,000 shares, all directly held through ARCH Venture Fund XIV, L.P., with the ARCH general partners and committee members sharing voting and disposition power.
-
Timing Tied to IPO Close
The purchase was dated the same day Aspen Neuroscience confirmed the November 2 closing of its IPO of 9,375,000 shares at $15.00 for about $140.6 million gross.
Analysis · ASPE · Life Sciences
Why it matters: the lead backers are adding exposure at the same level new investors paid. A group of ARCH Venture funds and Paul Berns bought 1.2 million shares at $15.00 for $18 million in the open market on the day the IPO closed. That is a large purchase for a newly public company, and it came in at the IPO price rather than below it. Because the buying is concentrated in a single 10% owner group, it reflects sponsor conviction rather than broad institutional demand.
How filings like this one have moved
In the 30 days to Nov 3, 2026, 40.9% of the 1143 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.37%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, ASPE was trading at $13.13 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $379.2M. The 52-week trading range was $11.60 to $14.90. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.